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Abstract
Objective. To investigate miRNA expression in relation to transcriptomic changes in plasmacytoid dendritic cells
(pDCs) in SLE and APS. pDCs are major producers of IFNa in SLE and APS, and miRNAs are emerging as regulators
of pDC activation.
Methods. miRNA and mRNA expression were measured by OpenArray and RNA-sequencing in pDCs of SLE,
SLE + APS (APS secondary to SLE) and primary APS (PAPS) patients. The miRNA profile of patients was compared
with the miRNA pattern of TLR7-activated pDCs.
Results. Among 131 miRNAs detected in pDCs, 35, 17 and 21 had a significantly lower level of expression in SLE,
SLE + APS and PAPS patients, respectively, as compared with healthy controls (HC). Notably, the miRNA profile did not
significantly differ between SLE and APS, but was driven by the presence or absence of an IFN signature. TLR7 stimu-
lation induced a general downregulation of miRNAs, similar to the pattern observed in SLE and APS patients. miR-361-
5p, miR-128-3p and miR-181a-2-3p expression was lower in patients with a high IFN signature (false discovery rate
<0.05) as compared with patients with a low IFN signature and HCs. Pathway enrichment on the overlap of miRNA
targets and upregulated genes from the RNAseq indicated that these miRNAs are involved in pDC activation and
apoptosis.
Conclusion. Lower miRNA expression in pDCs is shared between SLE, SLE + APS and PAPS and is related to the IFN
signature. As pDCs are the alleged source of the IFN signature in these patients, a better understanding of the molecular
mechanisms/pathways leading to pDC dysregulation in SLE and APS might open novel pathways for therapeutic
intervention.
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Rheumatology key messages
. Plasmacytoid dendritic cell miRNAs are downregulated in SLE and APS.
. Downregulation of plasmacytoid dendritic cells miRNAs reflects plasmacytoid dendritic cell activation in SLE and
APS.
. Reduced expression of miR-361-5p, miR-128-3p and miR-181a-2-3p affects pathways involved in plasmacytoid
dendritic cell activation.
Introduction
SLE is a chronic relapsing autoimmune disease that pre-
dominantly affects women of child-bearing age. In SLE,
immune complexes are deposited into tissues, including
skin, joint and kidneys, leading to tissue inflammation. The
pathogenesis of SLE is complex and includes derailments
of both the innate and adaptive immune system [1]. aPLs
are strongly associated with thrombotic events and preg-
nancy morbidity among patients with SLE. Approximately
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20% of SLE patients have APS, defined as the persistent
presence of aPLs in patients who have experienced at
least one thrombotic or obstetric complication [2]. APS
also affects patients without an underlying disease and
is then termed primary APS (PAPS). SLE and PAPS
share many pathologic features, from genetics to perturb-
ations in immune cells [3], although both conditions are
rarely studied together.
Both SLE and PAPS are characterized by an IFN signa-
ture [46], which stands for an increased expression of
type I IFNinducible genes. The IFN signature is detected
in 75% of SLE (±APS) patients and 50% of PAPS pa-
tients [5] and is linked to disease activity in SLE [6, 7] and
vascular disease in both SLE and PAPS [4]. Plasmacytoid
dendritic cells (pDCs) are considered the source of
elevated IFNa levels in SLE and APS because immune
complexes and aPL induce IFNa production by triggering
Toll-like receptor (TLR) 7 in pDCs [8, 9]. However, due to
their scarcity in the circulation (<0.5% of leucocytes), little
is known about the molecular alterations of pDCs in pa-
tients with SLE and APS.
miRNAs are short (1825 nucleotides) non-coding RNAs
that regulate gene expression at a post-transcriptional
level by binding to complementary sequences in target
genes, resulting in the reduced translation of these
target genes. miRNAs fine-tune cellular activation and dif-
ferentiation, and their dysregulation is emerging as an
underlying cause of autoimmunity [10]. The expression
of several miRNAs is altered in patients with autoimmune
diseases [10, 11]; however, most studies have used bulk
peripheral blood cells or plasma and are therefore of lim-
ited value in identifying the pathways regulated by altered
miRNA expression in a cell-specific manner.
Recent evidence suggests an important role for miRNAs
in regulating pDC activation [12, 13] and type I IFN re-
sponses [10]. Here we performed miRNA profiling and
RNA sequencing (RNAseq) on purified pDCs from patients
with SLE, SLE + APS and PAPS in order to identify
changes in miRNA expression and their target genes.
Our results support an increased activation state of
pDCs in SLE and APS, as reflected by a reduced expres-
sion of miRNAs in patients with high IFN signatures.
Methods
pDC isolation
pDCs were isolated from consecutive patients with SLE
(n= 20), SLE + APS (n= 10, APS secondary to SLE) and
PAPS (n= 10) and healthy controls (HCs, n= 12; supple-
mentary Table S1, available at Rheumatology online) from
peripheral blood mononuclear cells by positive selection
using the BDCA4 isolation kit, following the manufac-
turer’s instruction (Miltenyi). Classification criteria were
used to classify patients as SLE, SLE + APS or PAPS
[2, 14]. None of the patients had clinical evidence of an
ongoing infection at the time of enrolment. All participants
signed informed consent prior to the donation of blood,
and approval by the ethical committee from the University
Medical Centre Utrecht was obtained.
The purity of isolated pDCs was assessed by flow cyto-
metry using CD123 and BDCA2 fluorochrome-labelled
antibodies. The average purity was 92% (±3) and did
not differ between patients and controls.
miRNA profiling and RNAseq
RNA was extracted from isolated pDCs [using the Allprep
universal kit (Qiagen) according to the manufacturer’s in-
structions], and 10 ng was reverse transcribed using the
miRNA multiplex reverse transcriptase primer pools (either
v2.1 for pool A or v3.0 for pool B) and the TaqMan miRNA
reverse transcription kit (Life Technologies), allowing the
detection of 758 miRNAs, including housekeeping snRNA.
Reverse transcriptase products were pre-amplified using
the Megaplex PreAmp Primer pools A and B in the pres-
ence of the TaqMan PreAmp Master Mix (Life
Technologies), while using the following thermal cycler
conditions: 10 min, 95C; 2 min, 55C; 2 min, 72C and
16 cycles of 15 s, 95C and 4 min, 60C, and one single
cycle of 10 min, 96C. The miRNA Open Array profiling
was performed on the amplified cDNA, diluted 1:40, with
0.1TE buffer (pH 8.0) and subsequently 1:2 with
TaqMan Open Array MasterMix on the QuantStudio 12 K
Flex Real-Time PCR System (Life Technologies).
miRNA profiling data was analysed using the
Thermofisher Cloud (www.thermofisher.com). miRNA ex-
pression was normalized to the mean expression of
RNU44 and RNU48. Normalized expression values
(Crt) were used for statistical analysis. miRNAs with
Crt values >27 were set at 27. Only miRNAs with <10%
of missing values were included for further analysis. The
original data from the pDC miRNA profiling is available in
supplementary Table S2, available at Rheumatology
online. A publicly available miRNA profile (GSE21160)
generated using the same experimental approach in
pDCs activated by TLR7 agonist R837 (imiquimod) was
reanalysed using the same criteria.
RNAseq was performed on the same pDCs used for
miRNA profiling. RNAseq libraries were generated with
the TruSeq RNA Library Prep Kit (Illumina) and sequenced
on an Illumina HiSeq 4000, generating 20 million 100 bp
paired-end reads. The sample qualities were assessed by
FastQC, and the sequencing reads were aligned to the
human genome (GRCh38 build 79) using STAR aligner.
Gene expression data for the annotated genes was gen-
erated using HTSeq-count. The variance-stabilizing trans-
formation normalized expression values (normalized read
counts) were calculated using R-package DESeq2. Type I
IFN scores were calculated from normalized read counts
as previously described [5]. Patients were stratified by the
presence (IFN-high) or absence (IFN-low) of a type I IFN
signature by setting a threshold at the highest of the HCs.
Data handling and statistics
miRWALKm2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/
mirwalk2/) was used to search Targetscan and miRANDA for
potential target genes of selected miRNAs. Pathway enrich-
ment (based on the KEGG database) was performed on the
intersect of the miRNA predicted targets and upregulated
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genes from the RNAseq, using TopFunn (https://toppgene.
cchmc.org/enrichment.jsp). Pathways related to specific in-
fections were excluded.
Two-sided statistical tests were conducted with an a
level of 0.05. Differences between two groups were
tested using Welch’s t test. Correction for multiple testing
was performed by determining the false discovery rate
according to the BenjaminiHochberg procedure at a
q-value of 0.05.
Results
Global downregulation of pDC microRNAs in SLE and
APS patients
Out of 755 analysed miRNAs, 131 miRNAs were ex-
pressed in pDCs. Neither principal component analysis
(Fig. 1A) nor hierarchical clustering (Fig. 1D) of all ex-
pressed miRNAs clustered SLE patients as distinct from
APS patients, suggesting that these groups do not have
strongly differential miRNA patterns. When comparing
miRNA expression in SLE, SLE + APS and PAPS patients
with that in HCs, respectively, 36, 17 and 21 miRNA
were found differentially expressed (Fig. 1B; supplemen-
tary Table S1, available at Rheumatology online).
Remarkably, with the exception of 1 miRNA (miR-222),
all differentially expressed miRNAs had a lower expres-
sion in patients as compared with that in HCs, as evident
from the left-skewed volcano plots of these comparisons
(Fig. 1B); whereas the miRNA profiles of patients with SLE,
SLE + APS and PAPS did not show strong differences
(Fig. 1C). The miRNA expression in pDCs is therefore simi-
larly affected in SLE and APS.
TLR7 signalling induced a downregulation of pDC
microRNA expression
Several proteins are involved in the formation, transporta-
tion and stabilization of miRNAs, including the nucleases
DICER and DROSHA, which cut pre-miRNA transcripts
into mature miRNAs, exportin-5 (XPO5) [which exports
the miRNA out of the nucleus] and argonaute proteins






(A) Principal component analysis of all miRNAs expressed in pDCs of SLE, SLE+APS and PAPS patients and HCs.
(B) Volcanoplots of miRNA expression in SLE, SLE+APS and PAPS patients as compared with HCs or (C) among
patients. (D) Hierarchical clustering of pDC miRNAs. (E) Expression of genes related to the biogenesis and transport of
miRNA in pDCs as assessed by RNAseq. (F) Changes in the expression in purified pDCs upon stimulation by the TLR7
agonist R837. Relative miRNA expression was calculated as 2dCq, fold change was compared with medium control.
****P < 0.0001.
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(AGO1/AGO2) [which form the RNA-induced silencing
complex]. RNAseq on the same pDC samples that were
used for miRNA profiling, however, did not show signifi-
cant differences in the expression of these genes (Fig. 1E).
The global miRNA downregulation in pDCs of SLE and
APS seemed, therefore, not due to alterations in the
miRNA machinery. In contrast, activation of pDCs by
TLR7 agonists induced a global downregulation of
miRNA, to a similar extent as that seen in the patient sam-
ples (mean fold-change 0.45, Fig. 1F), suggesting that the
downregulation of miRNA in pDCs in SLE and APS reflects
pDC activation.
pDC miRNA expression was related to the type I IFN
signature in pDCs
RNAseq revealed increased type I IFN scores in pDCs of
SLE, SLE + APS and PAPS, which was strongest in the
patients with SLE and SLE + APS (Fig. 2A). Of the patient
samples, 58% (n= 23) were classified as IFN-high
(Fig. 2B). The IFN scores in pDCs strongly correlated
with the IFN scores we previously reported for monocytes
of the same samples [5] (Fig. 2C).
Upon stratification of the patients into those with or
without an IFN signature, miRNA expression was more
strongly reduced in IFN-high patients, compared with in
the IFN-low patients (Fig. 2D). Consequently, principal
component analysis and hierarchical clustering on all
miRNA showed a better separation of patients on the
basis of their IFN status with respect to their clinical dis-
ease (Fig. 2E and F). Three miRNAs (miR-361-5p, miR-
128-3p and miR-181-2-3p) were expressed at lower
levels (P< 0.001, false discovery rate< 0.05) in IFN-high
patients, compared with those without an IFN signature
and HCs, and were significantly correlated with the IFN
score (r = 0.44, 0.45 and 0.48, respectively,
P< 0.001) (Fig. 2G). These miRNAs were also downregu-
lated upon TLR7 ligation, whereas in SLE only the expres-
sion of mir-361-5p was significantly lower in patients with






(A) IFN scores of purified pDCs in patients stratified by clinical diagnosis or (B) IFN status. (C) Correlation of IFN scores
between monocytes and pDCs. (D) Volcanoplots of pDC miRNA expression in patients stratified by IFN status. (E and F)
Principal component analysis and hierarchical clustering of patients based on all miRNA stratified by IFN status. (G)
Expression (2dCq) of the three most significant miRNAs between patients with or without an IFN signature. (H) Pathway
enrichment of predicted target genes of miR-361-5p, miR-128-3p and miR-181a-2-3p and upregulated genes in pDCs of
patients with high IFN signatures. Percentages indicate the number of affected genes over the total genes annotated in
the pathway. *P < 0.05, **P < 0.01, ***P < 0.001, NS: non-significant.
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high disease activity (SLEDAI54, n= 12) as compared
with patients with low disease activity (SLEDAI<4,
n= 18, P= 0.03; data not shown).
Altered miRNA expression affected key signalling
pathways involved in pDC activation
One miRNA may regulate the expression of several hun-
dreds of genes. By integrating miRNA and mRNA expres-
sion data, we investigated the potential pathways affected
by altered miRNA expression in pDCs. An intersection of
the predicted target genes of miR-361-5p, miR-128-3p
and miR-181-2-3p and the upregulated genes from IFN-
high patients revealed 680 genes in common. Pathway
enrichment on these genes revealed that these miRNAs
are regulating the expression of genes involved in pDC
activation (retinoic acid-inducible gene I, RIG-I receptor
and nucleotide-binding oligomerization domain-like
receptors and tumor necrosis factor signalling) and apop-
tosis (Fig. 2H).
Discussion
Here we studied pDCs directly isolated from the periph-
eral blood of patients with SLE and APS and for the first
time analysed both their miRNome and transcriptome.
Strikingly, the overall miRNA expression was lower in
both SLE and APS patients vs controls, which was most
pronounced in patients with a high type I IFN signature.
TLR7 activation induced a similar profile of downregulated
miRNA expression in pDCs. Therefore, this indicates that
the profile of miRNA expression in pDCs of SLE and APS
patients is a reflection of pDC activation in vivo in these
patients.
A reduced expression of miRNAs has previously been
reported in neutrophils of SLE and APS patients [15]. This
reduced miRNA expression in neutrophils was shown to
be due to the decreased expression of the miRNA ma-
chinery in these cells [15]. In pDCs we did not see differ-
ential expression of these genes. As TLR7 signalling is
driving the production of IFNa by pDCs in SLE and APS
[8, 9], we assessed changes in miRNA expression after
TLR7 activation and observed that miRNA expression in
pDCs is highly sensitive to TLR7 stimulation, resulting in
the downregulation of the majority (92%) of miRNAs.
Thus, the mechanism behind miRNA downregulation in
neutrophils and pDCs of SLE and APS patients is
cell-specific.
Two previous studies on miRNA expression in mono-
cytes and neutrophils of SLE and PAPS patients reported
no differences in miRNA expression between patients with
either SLE or PAPS [15, 16]. Similarly, we observed no
major differences in miRNA expression between SLE,
SLE + APS and PAPS in pDCs. The dysregulation of
pDCs in terms of miRNA expression is therefore another
shared immunologic abnormality between patients with
SLE and APS [3], while the presence or absence of an
IFN signature, rather than having SLE or APS, is defining
miRNA expression in pDCs.
miR-361-5p, miR 128-3p and miR-181a-2-3p have not
been previously linked to the pathogenesis of SLE or APS
[10]. These miRNAs are specifically reduced in pDCs of
patients with high IFN signatures. The expression of the
targets of these miRNAs in pDCs of the same patients
suggests that these miRNAs are regulating the expression
of genes involved in key signalling pathways participating
in pDC activation, such as RIG-I signalling as well as pDC
apoptosis.
As pDCs are the alleged source of the type I IFN signa-
ture, we believe that a better understanding of the factors
(including miRNAs) underlying the dysregulation of pDCs
in SLE and APS could yield novel insights into the patho-
genesis of SLE and APS. Our data suggest that aber-
rances in miRNA expression may be key mediators in
regulating pDC activity and the immunopathology of SLE
and APS.
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